An increasing in the understanding of the complex interactions between the immune system and cancer has led to the development of immune checkpoint inhibitors, namely monoclonal antibodies directed against programmed death receptor 1 (PD-1), programmed death ligand 1 (PD-L1) and cytotoxic T-cell lymphocyte antigen-4 (CTLA-4) monoclonal antibodies, which promote T-cell activation with subsequent formation of anti-tumor effect, resulting in durable response and improvement in outcome. This evidence concerns the gene CD274 and neoplasm.